ClinicalTrials.gg
TerminatedNCT00807209Updated May 15, 2012Results posted

Dose Finding Posterolateral Thoracotomy Study

A Phase 2 interventional study of Low Dose SKY0402 and High Dose SKY0402 in Postoperative Pain, sponsored by Pacira Pharmaceuticals, Inc. Terminated at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-05-15.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor decision unrelated to safety

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
3
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 364 studies testing bupivacaine in Pain, Postoperative — 57 open to participants now, 60 under way, 5 of them phase 3. Bupivacaine · Pain, Postoperative.

Enrollment
344th of 364
3 · median 70
Started
2008
with 8 others
Phase 2
43 of 364
4 open now
Registered
16th of 364
by date
Lead sponsor
22 of 364
Pacira Pharmaceuticals, Inc

Among the 364 studies testing bupivacaine in Pain, Postoperative, this one is the 344th largest by enrollment, is one of 9 that started in 2008, is one of 43 in phase 2, and was the 16th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

57 of the 364 studies testing bupivacaine in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About bupivacaine

Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 364 studies testing bupivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

To review safety and effectiveness of two doses compared to current standard of care.

Read the detailed description

Evaluate the efficacy of intercostal nerve block using SKY0402 compared to epidural bupivacaine HCl in subjects undergoing posterolateral thoracotomy. The primary outcome metric for this will be the amount of rescue PCA fentanyl administered for breakthrough pain during the first 72 hours.

03

Conditions studied

  • Postoperative Pain

Keywords

  • Pain
  • postoperative
  • thoracotomy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women ≥ 18 years of age at the Screening Visit.
  • Scheduled to undergo a thoracotomy of at least 3 inches of intercostal incisional length or requiring insertion of an inter-rib spreader/retractor for a primary thoracic non-infectious indication under general anesthesia.
  • Able and willing to receive an epidural catheter for the treatment of postoperative pain.
  • American Society of Anesthesiology (ASA) Physical Class 1-4.
  • Able and willing to comply with all study visits and procedures.
  • Able to speak, read, and understand the language of the ICF, study questionnaires, and other instruments used for collecting subject-reported outcomes, in order to enable accurate and appropriate responses to pain scales and other required study assessments.
  • Willing and capable of providing written .

Exclusion criteria

Exclusion Criteria:

  • Known disease of any type.
  • Known pulmonary infectious disease.
  • Pregnancy, nursing, or planning to become pregnant during the study or within one month after study drug administration.
  • Use of any of the following medications within the times specified before surgery:

    1. Long-acting opioids within 3 days.
    2. Any opioid medication within 24 hours.
  • Concurrent painful physical condition or concurrent surgery that may require analgesic treatment in the postoperative period for pain that is not strictly related to the surgical site being administered study drug (e.g., significant pain from other joints, chronic neuropathic pain, concurrent abdominal surgery, etc.), which have the potential to confound the postoperative study assessments.
  • Body weight less than 50 kilograms (110 pounds).
  • History of or idiosyncratic reaction to amide-type local anesthetics, opioid medication, epinephrine, or sulfites.
  • to epinephrine, such as concurrent administration of ergot-type drugs, monoamine oxidase (MAO) inhibitors or antidepressants of tryptoline or imipramine types, conditions where the production or exacerbation of tachycardia could prove fatal (e.g., poorly controlled thyrotoxicosis or severe heart disease), or any other pathological conditions that might be aggravated by the effects of epinephrine.
  • Administration of an product within 30 days or 5 elimination half-lives of such investigational product, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study.
  • History of, suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.
  • Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the Investigator, may interfere with study assessments or compliance with the protocol.
  • Significant medical conditions or laboratory results that, in the opinion of the Investigator, indicate an increased vulnerability to study drugs and procedures, and expose the subject to an unreasonable risk as a result of participating in this clinical trial, such as: debilitating diseases, acute illnesses, hypotension, partial or complete conduction block, impaired cardiac function, untreated hypertension, advanced arteriosclerotic heart disease, cerebral vascular insufficiency, pre-existing abnormal neurological or neuromuscular disease (e.g., epilepsy, myasthenia gravis), advanced liver disease, sever renal impairment, advanced diabetes, co-morbid conditions associated with an status, such as blood dyscrasias, /AIDS, or recent chemotherapy.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    High Dose SKY0402

    Drug: High Dose SKY0402 · Drug: Fentanyl via PCA · Drug: Bupivacaine via epidural

  • Active comparator
    Standard of Care

    Drug: Placebo · Drug: Fentanyl via PCA · Drug: Bupivacaine via epidural

  • Experimental
    Low Dose SKY0402

    Drug: Low Dose SKY0402 · Drug: Fentanyl via PCA · Drug: Bupivacaine via epidural

Interventions

  • Bupivacaine, 15 mg/mL via epidural PLUS single total administration of 75mg SKY0402 (25 mg to each of three segments) in 4 mL volume each for a total of 12 mL via nerve block (intercostal)

  • Bupivacaine, 15 mg/mL via epidural PLUS single total administration of 150 mg (50 mg to each of three segments) in 4 mL volume each for a total of 12 mL via nerve block (intercostal)

  • DrugPlacebo

    Bupivacaine, 15 mg/mL per epidural PLUS administration of 4 mL Placebo to each of three nerves for a total of 12 mL (intercostal)

  • DrugFentanyl via PCA

    Fentanyl via PCA

  • DrugBupivacaine via epidural

    Bupivacaine via epidural

06

What researchers measure

Primary outcomes

  1. Amount of Rescue PCA Fentanyl Administered for Breakthrough Pain During the First 72 Hours.

    The primary outcome metric was to be the amount of rescue epidural fentanyl administered for breakthrough pain during the first 72 hours postoperatively. Patient-controlled analgesia (PCA) fentanyl intake was to be summarized for each treatment group as time to first use of rescue PCA fentanyl, amount of PCA fentanyl administered over 72 hours, and total amount of PCA fentanyl administered through a number of time intervals. However, efficacy analyses were not performed because the study was terminated early after only three subjects were enrolled.

    Time frame: 72 hours

07

Results

Posted May 15, 2012
Limitations and caveats
The study was terminated early due to Sponsor's decision, unrelated to safety. As there was only one patient in each group, no efficacy analyses were performed.

Participant flow

Participant flow — Overall Study
MilestoneHigh Dose SKY0402Standard of CareLow Dose SKY0402
Started111
Completed111
Not completed000

Outcome measures

PrimaryAmount of Rescue PCA Fentanyl Administered for Breakthrough Pain During the First 72 Hours.

The primary outcome metric was to be the amount of rescue epidural fentanyl administered for breakthrough pain during the first 72 hours postoperatively. Patient-controlled analgesia (PCA) fentanyl intake was to be summarized for each treatment group as time to first use of rescue PCA fentanyl, amount of PCA fentanyl administered over 72 hours, and total amount of PCA fentanyl administered through a number of time intervals. However, efficacy analyses were not performed because the study was terminated early after only three subjects were enrolled.

Time frame:
72 hours
Reported as:
Number · micrograms
Amount of Rescue PCA Fentanyl Administered for Breakthrough Pain During the First 72 Hours.
microgramsHigh Dose SKY0402Standard of CareLow Dose SKY0402
Amount of Rescue PCA Fentanyl Administered for Breakthrough Pain During the First 72 Hours.—00

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
High Dose SKY0402—0/1 (0%)1/1 (100%)
Standard of Care—0/1 (0%)1/1 (100%)
Low Dose SKY0402—0/1 (0%)1/1 (100%)
Most frequent other events
Most frequent other events
EventHigh Dose SKY0402Standard of CareLow Dose SKY0402
GasGastrointestinal disorders0/11/11/1
DiarrheaGastrointestinal disorders0/11/10/1
Swollen AnkleInjury, poisoning and procedural complications0/11/10/1
Difficulty breathingRespiratory, thoracic and mediastinal disorders0/10/11/1
Blood in nasal mucusRespiratory, thoracic and mediastinal disorders0/10/11/1
PainInjury, poisoning and procedural complications1/10/10/1
VomitingGastrointestinal disorders1/10/10/1
NauseaGastrointestinal disorders1/10/10/1

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)High Dose SKY0402Standard of CareLow Dose SKY0402Total
<=18 years0000
Between 18 and 65 years0011
>=65 years1102
Age Continuous
Age Continuous(years)High Dose SKY0402Standard of CareLow Dose SKY0402Total
Mean81 ± 075 ± 064 ± 073.3 ± 0
Sex: Female, Male
Sex: Female, Male(Participants)High Dose SKY0402Standard of CareLow Dose SKY0402Total
Female0112
Male1001
Region of Enrollment
Region of Enrollment(participants)High Dose SKY0402Standard of CareLow Dose SKY0402Total
United States1113
08

Study locations

5 sites
  • Lotus Clinical Research
    Pasadena, California 91105, United States
  • Florida Hospital
    Orlando, Florida 32801, United States
  • Memorial Hermann - Memorial City Medical Center
    Houston, Texas 77024, United States
  • Houston NW Medical Center
    Houston, Texas 77053, United States
  • Multicare Health System
    Tacoma, Washington 98405, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in May 2012, 3 years 3 months after primary completion. A results delay was requested in Aug 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2008
First posted
Dec 11, 2008
Start
Dec 2008
Primary completionActual
Feb 2009
CompletionActual
Feb 2009
Results delay requested
Aug 25, 2010
Results first posted
May 15, 2012
Last update
May 15, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00807209
Responsible party
Sponsor
First posted
Dec 11, 2008
Start date
Dec 2008
Primary completion
Feb 2009
Completion
Feb 2009
Results posted
May 15, 2012
Last update
May 15, 2012

Study contacts

Kay Warnott, RN, ACN-P
study director · Pacira Pharmaceuticals, Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion